Sign up
Pharma Capital

Advanced Oncotherapy adds another industry veteran to its senior management team

Dr Jonathan Farr has joined AVO as senior vice president of medical physics with immediate effect
protons
Dr Farr has written many papers on advances in proton treatments

Shares in Advanced Oncotherapy PLC (LON:AVO) nudged higher again on Wednesday after the proton therapy specialist added another industry veteran to its senior management team.

Dr Jonathan Farr has joined AVO as senior vice president of medical physics with immediate effect. He will not be taking a seat on the company’s board however.

Farr has an extensive background in the cancer treatment space and specialises in proton therapy, which AVO said fits in well with its goal of commercialising its next generation LIGHT proton therapy system.

He is the chief of radiation physics and associate professor at the St Jude Children’s Research Hospital in Memphis, Tennessee and is an international leading figure in medical physics, AVO added.

“Jonathan provides us with extensive expertise in proton therapy patient treatment,” said AVO chief executive Nicolas Serandour.

“He has a keen interest in innovation and is ideally suited to maximise the clinical benefits from LIGHT's next-generation technology.

“His appointment, alongside Ed Lee's, which was announced on 13 June, is a further endorsement of the ground-breaking work we are doing at Advanced Oncotherapy.”

As Serandour noted, Farr’s appointment comes just a day after the AIM-quoted company appointed fellow industry veteran Ed Lee  to the role of chief operating officer.

Shares gained 6.9% to trade at 19.5p

View full AVO profile

Advanced Oncotherapy Timeline

View All

Related Articles

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.